The SAFIR02-BREAST and SAFIR-PI3K phase II randomized studies enrolled 1462 patients with metastatic HER2− BC and evaluated the maintenance with targeted therapies (including alpelisib with fulvestrant), guided by genomics versus chemotherapy. This evidence concerns the gene PIK3CD and breast cancer.